amphetamine has been researched along with Dyskinesia, Drug-Induced in 48 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 7.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| "As a test of plausibility for the hypothesis that schizophrenia can result from abnormal brain, especially cerebral cortical, development, these studies examined whether, in the rat, disruption of brain development initiated on embryonic day (E) 17, using the methylating agent methylazoxymethanol acetate (MAM), leads to a schizophrenia-relevant pattern of neural and behavioral pathology." | 7.73 | A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. ( Geyer, MA; Ghajarnia, M; Grace, AA; Jentsch, JD; Moore, H, 2006) |
| "Cyclizine was observed to induce generalized chorea in a patient with mild lingual-facial-buccal dyskinesias." | 7.65 | Cyclizine-induced chorea. Observations on the influence of cyclizine on dopamine-related movement disorders. ( Klawans, HL; Moskovitz, C, 1977) |
| "Considering that ligands of metabotropic glutamate and GABA receptors may exert beneficial effects on schizophrenia, we assessed the actions of the first mGlu>4-selective orthosteric agonist, LSP4-2022, in several tests reflecting positive, negative, and cognitive symptoms of schizophrenia." | 3.83 | Involvement of GABAB Receptor Signaling in Antipsychotic-like Action of the Novel Orthosteric Agonist of the mGlu4 Receptor, LSP4-2022. ( Acher, F; Gruca, P; Lasoń-Tyburkiewicz, M; Marciniak, M; Papp, M; Pilc, A; Wierońska, JM; Woźniak, M, 2016) |
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 3.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| "As a test of plausibility for the hypothesis that schizophrenia can result from abnormal brain, especially cerebral cortical, development, these studies examined whether, in the rat, disruption of brain development initiated on embryonic day (E) 17, using the methylating agent methylazoxymethanol acetate (MAM), leads to a schizophrenia-relevant pattern of neural and behavioral pathology." | 3.73 | A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. ( Geyer, MA; Ghajarnia, M; Grace, AA; Jentsch, JD; Moore, H, 2006) |
| "Cyclizine was observed to induce generalized chorea in a patient with mild lingual-facial-buccal dyskinesias." | 3.65 | Cyclizine-induced chorea. Observations on the influence of cyclizine on dopamine-related movement disorders. ( Klawans, HL; Moskovitz, C, 1977) |
| "Thus, mouse strains selected for a particular trait may be leveraged to generate hypothesis-driven studies aimed at clarifying the potential role played by the environment in modulating the exhibition of the symptoms of interest." | 1.40 | A behavioural test battery to investigate tic-like symptoms, stereotypies, attentional capabilities, and spontaneous locomotion in different mouse strains. ( Ceci, C; Laviola, G; Macrì, S; Proietti Onori, M, 2014) |
| "Haloperidol is an antipsychotic drug associated with the development of movement disorders." | 1.37 | Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats. ( Barcelos, RC; Beck, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Ourique, AF; Pase, CS; Reckziegel, P, 2011) |
| " We now show that they are associated with the chronic administration of L-DOPA prior to the transplantation surgery." | 1.35 | Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. ( Brundin, P; Cenci, MA; Lane, EL; Vercammen, L, 2009) |
| " Dose-response analysis for total AIM scores yielded a levodopa ED50 value of 3." | 1.34 | Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. ( Belknap, JK; Johnson, SW; Kozell, LB; Munhall, AC; Putterman, DB, 2007) |
| "Although oral administration of L-Dopa remains the best therapy for Parkinson disease, its long-term administration causes the appearance of abnormal involuntary movements such as dyskinesia." | 1.33 | Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. ( Benabid, AL; Berger, F; Buggia, V; Gilbert, F; Lévesque, D; Sgambato-Faure, V, 2005) |
| "Aripiprazole is a novel antipsychotic drug, which displays partial agonist activity at the dopamine D(2) receptor." | 1.33 | Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. ( Clarke, K; Davies, CH; Forbes, IT; Gribble, A; Hill, M; Jones, DN; Newson, M; Reavill, C; Rourke, C; Scott, C; Westaway, J; Wood, MD, 2006) |
| "Neither (-)-3-PPP nor SND 919 produced dystonia, but had observable dopamine D2 receptor agonistic effects, (-)-3-PPP producing emesis at 1-4 mg/kg and SND 919 producing motoric unrest and stereotypy at 0." | 1.29 | Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol. ( Gerlach, J; Peacock, L, 1993) |
| "Rats with ablated frontal sensorimotor cortex and one with ablated sensorimotor connections to forebrain showed more vacuous chewing movements following 6-week chronic administration of a neuroleptic than did occipitally damaged rats or normal controls who were treated in the same way." | 1.26 | Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia. ( Glassman, HN; Glassman, RB, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (20.83) | 18.7374 |
| 1990's | 5 (10.42) | 18.2507 |
| 2000's | 16 (33.33) | 29.6817 |
| 2010's | 17 (35.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leino, S | 1 |
| Koski, SK | 1 |
| Hänninen, R | 1 |
| Tapanainen, T | 1 |
| Rannanpää, S | 1 |
| Salminen, O | 1 |
| Smith, GA | 1 |
| Heuer, A | 1 |
| Klein, A | 1 |
| Vinh, NN | 1 |
| Dunnett, SB | 1 |
| Lane, EL | 3 |
| Shin, E | 4 |
| Lisci, C | 1 |
| Tronci, E | 3 |
| Fidalgo, C | 1 |
| Stancampiano, R | 1 |
| Björklund, A | 5 |
| Carta, M | 5 |
| Proietti Onori, M | 1 |
| Ceci, C | 1 |
| Laviola, G | 1 |
| Macrì, S | 1 |
| Rogers, JT | 1 |
| Devoto, P | 1 |
| Ledesma, JC | 1 |
| Miquel, M | 1 |
| Pascual, M | 1 |
| Guerri, C | 1 |
| Aragon, CM | 1 |
| Collier, TJ | 1 |
| O'Malley, J | 1 |
| Rademacher, DJ | 1 |
| Stancati, JA | 1 |
| Sisson, KA | 1 |
| Sortwell, CE | 1 |
| Paumier, KL | 1 |
| Gebremedhin, KG | 1 |
| Steece-Collier, K | 1 |
| Keber, U | 1 |
| Klietz, M | 1 |
| Carlsson, T | 1 |
| Oertel, WH | 1 |
| Weihe, E | 1 |
| Schäfer, MK | 1 |
| Höglinger, GU | 1 |
| Depboylu, C | 1 |
| Woźniak, M | 1 |
| Acher, F | 1 |
| Marciniak, M | 1 |
| Lasoń-Tyburkiewicz, M | 1 |
| Gruca, P | 1 |
| Papp, M | 1 |
| Pilc, A | 1 |
| Wierońska, JM | 1 |
| Larramendy, C | 1 |
| Taravini, IR | 1 |
| Saborido, MD | 1 |
| Ferrario, JE | 1 |
| Murer, MG | 1 |
| Gershanik, OS | 1 |
| Vercammen, L | 1 |
| Cenci, MA | 2 |
| Brundin, P | 2 |
| Pérez-Rial, S | 1 |
| García-Gutiérrez, MS | 1 |
| Molina, JA | 1 |
| Pérez-Nievas, BG | 1 |
| Ledent, C | 1 |
| Leiva, C | 1 |
| Leza, JC | 1 |
| Manzanares, J | 1 |
| Bordia, T | 1 |
| Campos, C | 1 |
| McIntosh, JM | 1 |
| Quik, M | 1 |
| Shi, X | 1 |
| McGinty, JF | 1 |
| Benvegnú, DM | 1 |
| Barcelos, RC | 1 |
| Boufleur, N | 1 |
| Reckziegel, P | 1 |
| Pase, CS | 1 |
| Ourique, AF | 1 |
| Beck, RC | 1 |
| Bürger, ME | 1 |
| Lodge, DJ | 1 |
| Grace, AA | 2 |
| Garcia, J | 1 |
| Winkler, C | 2 |
| Bezard, E | 1 |
| Pioli, EY | 1 |
| Li, Q | 1 |
| Porras, G | 1 |
| Zhao, H | 1 |
| He, X | 1 |
| Thurkauf, A | 1 |
| Hoffman, D | 1 |
| Kieltyka, A | 1 |
| Brodbeck, R | 1 |
| Primus, R | 1 |
| Wasley, JW | 1 |
| Lamango, NS | 1 |
| Ayuk-Takem, LT | 1 |
| Nesby, R | 1 |
| Zhao, WQ | 1 |
| Charlton, CG | 1 |
| Chen, JF | 1 |
| Fredduzzi, S | 1 |
| Bastia, E | 1 |
| Yu, L | 1 |
| Moratalla, R | 1 |
| Ongini, E | 1 |
| Schwarzschild, MA | 1 |
| Dall'Igna, OP | 1 |
| Tort, AB | 1 |
| Souza, DO | 1 |
| Lara, DR | 1 |
| Sgambato-Faure, V | 1 |
| Buggia, V | 1 |
| Gilbert, F | 1 |
| Lévesque, D | 1 |
| Benabid, AL | 1 |
| Berger, F | 1 |
| Moore, H | 1 |
| Jentsch, JD | 1 |
| Ghajarnia, M | 1 |
| Geyer, MA | 1 |
| Wood, MD | 1 |
| Scott, C | 1 |
| Clarke, K | 1 |
| Westaway, J | 1 |
| Davies, CH | 1 |
| Reavill, C | 1 |
| Hill, M | 1 |
| Rourke, C | 1 |
| Newson, M | 1 |
| Jones, DN | 1 |
| Forbes, IT | 1 |
| Gribble, A | 1 |
| Fleming, SM | 1 |
| Salcedo, J | 1 |
| Hutson, CB | 1 |
| Rockenstein, E | 1 |
| Masliah, E | 1 |
| Levine, MS | 1 |
| Chesselet, MF | 1 |
| Putterman, DB | 2 |
| Munhall, AC | 1 |
| Kozell, LB | 1 |
| Belknap, JK | 1 |
| Johnson, SW | 2 |
| Kuan, WL | 1 |
| Zhao, JW | 1 |
| Barker, RA | 1 |
| Paquette, MA | 1 |
| Brudney, EG | 1 |
| Meshul, CK | 1 |
| Berger, SP | 1 |
| Glassman, RB | 1 |
| Glassman, HN | 1 |
| Wray, SR | 1 |
| Melville, GN | 1 |
| Grell, GA | 1 |
| Edge, PC | 1 |
| Hyttel, J | 1 |
| Christensen, AV | 1 |
| Arnt, J | 1 |
| Goetz, CG | 1 |
| Klawans, HL | 2 |
| Carvey, P | 1 |
| Wyatt, RJ | 1 |
| Potkin, SG | 1 |
| Kleinman, JE | 1 |
| Weinberger, DR | 1 |
| Luchins, DJ | 1 |
| Jeste, DV | 1 |
| Migler, BM | 1 |
| Warawa, EJ | 1 |
| Malick, JB | 1 |
| Peacock, L | 2 |
| Gerlach, J | 2 |
| See, RE | 1 |
| Neisewander, JL | 1 |
| Castañeda, E | 1 |
| Davis, DA | 1 |
| Elson, HJ | 1 |
| Sussman, AN | 1 |
| Hansen, L | 1 |
| Mørkeberg, F | 1 |
| Olds, ME | 1 |
| Jacques, DB | 1 |
| Kopyov, O | 1 |
| Adler, CM | 1 |
| Malhotra, AK | 1 |
| Elman, I | 1 |
| Pickar, D | 1 |
| Breier, A | 1 |
| Bürki, HR | 1 |
| Moskovitz, C | 1 |
| Crayton, JW | 1 |
| Smith, RC | 1 |
| Klass, D | 1 |
| Chang, S | 1 |
| Ericksen, SE | 1 |
| Lee, TH | 1 |
| Ellinwood, EH | 1 |
| Nishita, JK | 1 |
| Levy, AD | 1 |
| Ellison, GD | 1 |
4 reviews available for amphetamine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Current concepts of abnormal motor disorder: an experimental model of attentional deficit disorder.
Topics: Amphetamine; Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Avoidance | 1981 |
Animal models of tardive dyskinesia: their use in the search for new treatment methods.
Topics: Age Factors; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Carbidopa; Corpus Striatum; Di | 1983 |
The schizophrenia syndrome. Examples of biological tools for subclassification.
Topics: Amphetamine; Blood Platelets; Dominance, Cerebral; Dyskinesia, Drug-Induced; Functional Laterality; | 1981 |
Dopamine receptor sensitivity changes with chronic stimulants.
Topics: Amphetamine; Animals; Behavior; Brain; Dopamine; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; R | 1988 |
44 other studies available for amphetamine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain; Central Nervous System Stimulants; Dopamine; Dopa | 2018 |
Amphetamine-induced dyskinesia in the transplanted hemi-Parkinsonian mouse.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Cell Transplantation; Corpus Striatum | 2012 |
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease | 2014 |
A behavioural test battery to investigate tic-like symptoms, stereotypies, attentional capabilities, and spontaneous locomotion in different mouse strains.
Topics: Amphetamine; Amphetamines; Animals; Attention; Central Nervous System Stimulants; Circadian Rhythm; | 2014 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benz | 2014 |
Induction of brain cytochrome P450 2E1 boosts the locomotor-stimulating effects of ethanol in mice.
Topics: Acetone; Amphetamine; Animals; Brain; Central Nervous System Depressants; Central Nervous System Sti | 2014 |
Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration.
Topics: Aging; Amphetamine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Ph | 2015 |
Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Amphetamine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Dru | 2015 |
Involvement of GABAB Receptor Signaling in Antipsychotic-like Action of the Novel Orthosteric Agonist of the mGlu4 Receptor, LSP4-2022.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cyclopentanes; Disease Models, Animal; Dizocilpine Malea | 2016 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease M | 2008 |
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Sti | 2009 |
Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.
Topics: Amphetamine; Analysis of Variance; Animals; Benserazide; Brain; Dopamine Agents; Dyskinesia, Drug-In | 2011 |
Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization.
Topics: Amphetamine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Bridged Bicyclo Compo | 2010 |
D1 and D2 dopamine receptors differentially mediate the activation of phosphoproteins in the striatum of amphetamine-sensitized rats.
Topics: Amphetamine; Animals; Area Under Curve; Behavior, Animal; Benzazepines; Central Nervous System Stimu | 2011 |
Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Chemical Phenomena; Disease Models, Animal; Dyskinesia, | 2011 |
Divergent activation of ventromedial and ventrolateral dopamine systems in animal models of amphetamine sensitization and schizophrenia.
Topics: Action Potentials; Amphetamine; Animals; Central Nervous System Stimulants; Corpus Striatum; Disease | 2012 |
Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study.
Topics: Amphetamine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamin | 2012 |
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinso | 2012 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, | 2013 |
Indoline and piperazine containing derivatives as a novel class of mixed D(2)/D(4) receptor antagonists. Part 2: asymmetric synthesis and biological evaluation.
Topics: Amphetamine; Animals; Antipsychotic Agents; Binding, Competitive; Catalepsy; Central Nervous System | 2002 |
Inhibition mechanism of S-adenosylmethionine-induced movement deficits by prenylcysteine analogs.
Topics: Amphetamine; Animals; Body Temperature; Central Nervous System Stimulants; Cystine; Drug Synergism; | 2003 |
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Dis | 2003 |
Cinnarizine has an atypical antipsychotic profile in animal models of psychosis.
Topics: Amphetamine; Animals; Antipsychotic Agents; Calcium Channel Blockers; Catalepsy; Central Nervous Sys | 2005 |
Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic | 2005 |
The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamin | 2006 |
A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Brain; Central Nervous System Stimulan | 2006 |
Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.
Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Binding, Competitive; Bi | 2006 |
Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
Topics: alpha-Synuclein; Amphetamine; Animals; Apomorphine; Behavior, Animal; Benserazide; Brain; Disease Mo | 2006 |
Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Disease Models, Animal; Dopamin | 2007 |
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nerv | 2008 |
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.
Topics: Adrenergic Agents; Amphetamine; Animals; Anti-Anxiety Agents; Behavior, Animal; Dextromethorphan; Di | 2008 |
Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain; Chlorpromazine; Di | 1980 |
Neuroleptic classification: implications for tardive dyskinesia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Biperiden; Drug Interactions; Drug Tolerance; Dyskinesia | 1983 |
Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Basal Ganglia Diseases; | 1993 |
Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
Topics: Administration, Oral; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Benzothiazoles; | 1993 |
Assessment of striatal extracellular dopamine and dopamine metabolites by microdialysis in haloperidol-treated rats exhibiting oral dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-In | 1993 |
Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia.
Topics: Adrenergic Agents; Amphetamine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Dru | 1996 |
Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
Topics: Amphetamine; Animals; Arousal; Basal Ganglia Diseases; Benzazepines; Benzofurans; Cebus; Dopamine Ag | 1999 |
Entopeduncular lesions facilitate and thalamic lesions depress spontaneous and drug-evoked motor behavior in the hemiparkinsonian rat.
Topics: Amphetamine; Animals; Apomorphine; Denervation; Disease Models, Animal; Dopamine Agonists; Dyskinesi | 2001 |
Amphetamine-induced dopamine release and post-synaptic specific binding in patients with mild tardive dyskinesia.
Topics: Adult; Amphetamine; Analysis of Variance; Binding Sites; Corpus Striatum; Dopamine; Dopamine Antagon | 2002 |
Biochemical methods for predicting the occurrence of tardive dyskinesia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Atropine; Caudate Nucleus; Dyskinesia, Drug-Induced; Hal | 1979 |
Cyclizine-induced chorea. Observations on the influence of cyclizine on dopamine-related movement disorders.
Topics: Aged; Amphetamine; Animals; Apomorphine; Behavior, Animal; Chorea; Cyclizine; Dyskinesia, Drug-Induc | 1977 |
Electrophysiological (H-reflex) studies of patients with tardive dyskinesia.
Topics: Amphetamine; Apomorphine; Deanol; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electr | 1977 |
Interaction between chronic amphetamine and neuroleptic treatments on oral behavior in rats.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Drug Interactions; Dyskinesia, Drug-Induced; Fe | 1987 |